Ma D, Mellon J, Niederkorn J Y
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas 75235-9057, USA.
Br J Ophthalmol. 1997 Sep;81(9):778-84. doi: 10.1136/bjo.81.9.778.
To determine optimal conditions for enhancing corneal allograft survival through oral administration of donor specific corneal cells.
A mouse model of penetrating keratoplasty was used to evaluate the efficacy and optimal conditions for preventing immunological rejection of corneal allografts. C3H corneal grafts were transplanted orthotopically to CB6F1 recipients and represented mismatches at the entire major histocompatibility complex (MHC) and multiple minor histocompatibility loci. Tissue cultured C3H corneal epithelial and endothelial cells were administered orally to CB6F1 mice before or shortly after the application of orthotopic C3H corneal allografts. Cultured C3H corneal cells were conjugated with the non-toxic B subunit of cholera toxin as a means of preferentially inducing oral tolerance.
Ten oral doses of donor cells administered before keratoplasty reduced the incidence of corneal graft rejection from 100% in untreated hosts to 54% in orally tolerised mice. Conjugation of cholera toxin to corneal cells significantly enhanced the efficacy of oral tolerance such that only 9% of the mice fed 10 doses of cholera toxin conjugated cells rejected their corneal grafts. Even a single oral inoculation of corneal cells conjugated to cholera toxin was able to reduce corneal graft rejection by 36%.
Oral administration of donor specific cells greatly enhances corneal graft survival. Use of cholera toxin adjuvant markedly enhances the efficacy of oral tolerance such that even a single oral dose of donor cells significantly reduces the incidence of rejection. The results support the clinical feasibility of this novel strategy for preventing immunological rejection of corneal transplants.
通过口服供体特异性角膜细胞来确定提高角膜移植存活率的最佳条件。
采用穿透性角膜移植小鼠模型评估预防角膜移植免疫排斥的疗效和最佳条件。将C3H角膜移植物原位移植到CB6F1受体小鼠上,这些移植物在整个主要组织相容性复合体(MHC)和多个次要组织相容性位点存在错配。在原位移植C3H角膜移植物之前或之后不久,将组织培养的C3H角膜上皮细胞和内皮细胞口服给予CB6F1小鼠。将培养的C3H角膜细胞与霍乱毒素的无毒B亚基偶联,作为优先诱导口服耐受的一种手段。
在角膜移植术前口服十次供体细胞,可使角膜移植排斥发生率从未经处理的宿主中的100%降至口服耐受小鼠中的54%。将霍乱毒素与角膜细胞偶联可显著增强口服耐受的效果,使得喂食十次霍乱毒素偶联细胞的小鼠中只有9%的小鼠发生角膜移植排斥。即使单次口服接种与霍乱毒素偶联的角膜细胞也能使角膜移植排斥降低36%。
口服供体特异性细胞可大大提高角膜移植存活率。使用霍乱毒素佐剂可显著增强口服耐受的效果,以至于即使单次口服供体细胞也能显著降低排斥发生率。这些结果支持了这种预防角膜移植免疫排斥新策略的临床可行性。